Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial
Por:
Jabbour E, Lussana F, Martínez-Sánchez P, Torrent A, Rifón JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernández-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P and Kantarjian H
Publicada:
1 jul 2025
Ahead of Print:
1 jul 2025
Resumen:
Background Two doses of subcutaneous blinatumomab in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia were identified as preliminary recommended phase 2 doses, based on the dose-escalation phase of this multicentre single-arm, phase 1/2 trial. Here, we aim to further study the safety, activity, and pharmacokinetics of these doses in all participants who have received them, including those treated in the completed phase 1b expansion part of the study. Methods We did a post-hoc analysis of data from patients enrolled in the dose-escalation and dose-expansion phases and in the pharmacokinetic evaluation cohort of this multicentre, single-arm, phase 1/2 study. Patients were recruited from 44 hospitals in 11 countries. Eligible participants were aged 18 years or older with relapsed or refractory B-cell acute lymphoblastic leukaemia, at least 5% of blasts in the bone marrow, and an Eastern Cooperative Oncology Group performance status of 2 or lower. Patients received either 250 pg subcutaneous blinatumomab once daily in week 1 of cycle 1 and then 500 pg three times weekly thereafter (250 pg/500 pg group), or 500 pg and then 1000 pg subcutaneous blinatumomab on the same schedule (500 pg/1000 pg group), previously identified as the preliminary recommended phase 2 doses. Each treatment cycle included a 4-week treatment period and a 1-week treatment-free interval. Patients received between two and five cycles. The primary endpoint for the dose-expansion phase was complete remission or complete remission with partial haematological recovery within the first two cycles, which was used as the primary outcome for this study. Data were pooled from all cohorts of the same dose level to form two dose groups. The response rates, adverse event incidence, and pharmacokinetics were summarised in each dose group separately and compared descriptively. Response was calculated with two-sided exact 80% CIs (Clopper-Pearson method). This study is registered with ClinicalTrials.gov, NCT04521231; phase 1 is complete, and phase 2 is active but not recruiting. Findings Participants were recruited from Oct 18, 2021, to Sept 23, 2024, and median follow-up for the analyses was 5 months (IQR 3-9). Of the 88 patients included in the analysis at the data cutoff of Nov 28, 2024, 36 (41%) were treated with the 250 pg/500 pg regimen and 52 (59%) with the 500 pg/1000 pg regimen. The enrolled population comprised 55 (63%) male and 33 (38%) female participants; 56 (64%) were White, six (7%) Asian, three (3%) Black or African American, two (2%) American Indian or Alaska Native, and 20 (23%) other. Hispanic or Latino ethnicity was reported for 33 (38%) patients. 27 (75%) of 36 patients in the 250 pg/500 pg group and 41 (79%) of 52 in the 500 pg/1000 pg group showed complete remission or complete remission with partial haematological recovery. The most common grade 3-4 adverse events were neutropenia (19 [22%] patients), cytokine release syndrome (CRS; 18 [20%] patients), and immune effector cell-associated neurotoxicity syndrome (ICANS; 15 [17%] patients). Serious adverse events occurred in 70 (80%) of 88 patients and included CRS (33 [38%] patients), ICANS (20 [23%] patients), and neurotoxicity (six [7%] patients). No treatment-related deaths were reported. Consistent pharmacokinetics with dose-proportional exposures was observed following subcutaneous administration.
Based on the totality of data, including efficacy, safety, and pharmacokinetic data, the subcutaneous blinatumomab dose regimen of 250 pg/500 pg was selected as the recommended phase 2 dose. Interpretation Treatment with subcutaneous blinatumomab at the two dose regimens of 250 pg/500 pg and 500 pg/1000 pg resulted in promising preliminary activity and a manageable safety profile in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. The phase 2 part of the trial is ongoing to further evaluate subcutaneous blinatumomab activity and duration of response. Funding Amgen. Copyright (c) 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Filiaciones:
Jabbour E:
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Lussana F:
Department of Oncology and Haematology-Oncology, University of Milan, Milan, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
Martínez-Sánchez P:
Haematology Department, Hospital Universitario 12 de Octubre, Complutense University, Madrid, Spain
:
Clinical Haematology Department, Catalan Institute of Oncology, Germans Trias i Pujol Hospital, Badalona, Spain
Josep Carreras Leukaemia Research Institute, Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain
Rifón JJ:
Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain
Agrawal V:
Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA, USA
Tormo M:
Haematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain
Cassaday RD:
Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
Cluzeau T:
Côte d'Azur University, CHU Nice, Nice, France
Huguet F:
Department of Haematology, Toulouse Oncopole University Cancer Institute, CHU Toulouse, Toulouse, France
Papayannidis C:
Azienda University Hospital of Bologna IRCSS, Seràgnoli Institute of Haematology, Bologna, Italy
Hernández-Rivas JM:
Department of Medicine, University of Salamanca, Salamanca, Spain
Department of Haematology, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain
Rijneveld A:
Department of Haematology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
Fleming S:
Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia
Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
Vucinic V:
Department of Haematology, Cell Therapy and Haemostaseology and Centre for Infectious Diseases, University Hospital Leipzig, Leipzig, Germany
Böll B:
Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Ikezoe T:
Department of Hematology, Fukushima Medical University, Fukushima, Japan
Abdul-Hay M:
Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA
Savoie ML:
Arthur J E Child Comprehensive Cancer Center, University of Calgary, Calgary, Canada
Schuh AC:
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Berthon C:
Cancer Heterogeneity, Plasticity and Resistance to Therapies, UMR9020 CNRS-UMR1277 Inserm, University of Lille, Lille, France
Schwartz S:
Department of Haematology, Oncology and Cancer Immunology, Charité-University Hospital Berlin, Berlin, Germany
Chiaretti S:
School of Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
Yuda J:
Department of Hematology and Oncology, National Cancer Center Hospital East, Chiba, Japan
Miyazaki T:
Department of Hematology, Yokohama City University Medical Center, Kanagawa, Japan
González-Campos J:
Department of Haematology, Virgen del Rocío University Hospital-Higher Council for Scientific Research-University of Seville, Institute of Biomedicine of Seville, Seville, Spain
Chen Y:
Amgen, Thousand Oaks, CA, USA
Wong H:
Amgen, Thousand Oaks, CA, USA
Choudhry J:
Amgen, Thousand Oaks, CA, USA
Zugmaier G:
Amgen Research (Munich), Munich, Germany
Guest E:
Amgen, Thousand Oaks, CA, USA
Gordon P:
Amgen, Thousand Oaks, CA, USA
Kantarjian H:
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Green Published
|